Cure My Disease

Don't miss your cure!

 Log in / Sign up

New narcolepsy drug TAK-861 put to the test in withdrawal trial

NCT ID NCT07363720

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the drug's effect lasts and is better than no treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TAK-861
What this could lead to
If it works, this could provide a new treatment option to control excessive daytime sleepiness and sudden muscle weakness in people with narcolepsy type 1.
What could go wrong
This is a small Phase 3 trial with only 88 participants, and the main test is a short 4-week withdrawal period. The drug may not prove better than placebo, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY TYPE 1 (NT1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY TYPE 1 (NT1) NARCOLEPSY WITH CATAPLEXY

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Takeda Site 1

    RECRUITING

    Montpellier, 34295, France

  • Takeda Site 10

    RECRUITING

    Barcelona, 08036, Spain

  • Takeda Site 11

    RECRUITING

    Alzira, Valencia, 46600, Spain

  • Takeda Site 12

    RECRUITING

    Vitoria-Gasteiz, Alava, 01004, Spain

  • Takeda Site 13

    RECRUITING

    Barmelweid, Canton of Aargau, 5017, Switzerland

  • Takeda Site 14

    RECRUITING

    Bern, 3010, Switzerland

  • Takeda Site 15

    RECRUITING

    Redwood City, California, 94063, United States

  • Takeda Site 16

    RECRUITING

    Cincinnati, Ohio, 45245, United States

  • Takeda Site 17

    RECRUITING

    Columbia, South Carolina, 29201, United States

  • Takeda Site 18

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Takeda Site 19

    RECRUITING

    Brandon, Florida, 33511, United States

  • Takeda Site 2

    RECRUITING

    Paris, 75013, France

  • Takeda Site 20

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Takeda Site 21

    RECRUITING

    Austin, Texas, 78731, United States

  • Takeda Site 22

    RECRUITING

    Miami, Florida, 33155, United States

  • Takeda Site 23

    RECRUITING

    Southfield, Michigan, 48075, United States

  • Takeda Site 24

    RECRUITING

    Durham, North Carolina, 27710-4000, United States

  • Takeda Site 25

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • Takeda Site 3

    RECRUITING

    Toulouse, 31059, France

  • Takeda Site 4

    RECRUITING

    Schwerin, Mecklenburg-Vorpommern, 19053, Germany

  • Takeda Site 5

    RECRUITING

    Berlin, 10117, Germany

  • Takeda Site 6

    RECRUITING

    Bologna, Emilia-Romagna, 40139, Italy

  • Takeda Site 7

    RECRUITING

    Rome, Lazio, 00133, Italy

  • Takeda Site 8

    RECRUITING

    Heemstede, 2103 SW, Netherlands

  • Takeda Site 9

    RECRUITING

    Madrid, 28043, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.